Unlabelled: GAD-alum given into lymph nodes to Type 1 diabetes (T1D) patients participating in a multicenter, randomized, placebo-controlled double-blind study seemed to have a positive effect for patients with DR3DQ2 haplotype, who showed better preservation of C-peptide than the placebo group. Here we compared the immunomodulatory effect of GAD-alum administered into lymph nodes of patients with T1D versus placebo with focus on patients with DR3DQ2 haplotype.

Methods: GAD autoantibodies, GADA subclasses, GAD-induced cytokine secretion (Luminex panel) and proliferation of peripheral mononuclear cells were analyzed in T1D patients (n=109) who received either three intra-lymphatic injections (one month apart) with 4 µg GAD-alum and oral vitamin D supplementation (2000 IE daily for 120 days), or placebo.

Results: Higher GADA, GADA subclasses, GAD-induced proliferation and cytokine secretion was observed in actively treated patients after the second injection of GAD-alum compared to the placebo group. Following the second injection of GAD-alum, actively treated subjects with DR3DQ2 haplotype had higher GAD-induced secretion of several cytokine (IL4, IL5, IL7, IL10, IL13, IFNγ, GM-CSF and MIP1β) and proliferation compared to treated individuals without DR3DQ2. Stratification of samples from GAD-alum treated patients according to C-peptide preservation at 15 months revealed that "good responder" individuals with better preservation of C-peptide secretion, independently of the HLA haplotype, had increased GAD-induced proliferation and IL13 secretion at 3 months, and a 2,5-fold increase of IL5 and IL10 as compared to "poor responders". The second dose of GAD-alum also induced a more pronounced cytokine secretion in "good responders" with DR3DQ2, compared to few "good responders" without DR3DQ2 haplotype.

Conclusion: Patients with DR3DQ2 haplotype had a distinct early cellular immune response to GAD-alum injections into the lymph node, and predominant GAD-induced IL13 secretion and proliferation that seems to be associated with a better clinical outcome. If confirmed in the ongoing larger randomized double-blind placebo-controlled clinical trial (DIAGNODE-3), including only patients carrying DR3DQ2 haplotype, these results might be used as early surrogate markers for clinical efficacy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933867PMC
http://dx.doi.org/10.3389/fimmu.2023.1112570DOI Listing

Publication Analysis

Top Keywords

dr3dq2 haplotype
20
patients dr3dq2
16
cytokine secretion
12
patients
11
dr3dq2
9
type diabetes
8
immune response
8
gad-alum
8
lymph nodes
8
t1d patients
8

Similar Publications

Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial.

Int J Mol Sci

January 2025

Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, 581 83 Linköping, Sweden.

Immunotherapies aimed at preserving residual beta cell function in type 1 diabetes have been successful, although the effect has been limited, or raised safety concerns. Transient effects often observed may necessitate redosing to prolong the effect, although this is not always feasible or safe. Treatment with intralymphatic GAD-alum has been shown to be tolerable and safe in persons with type 1 diabetes and has shown significant efficacy to preserve C-peptide with associated clinical benefit in individuals with the human leukocyte antigen DR3DQ2 haplotype.

View Article and Find Full Text PDF

There is variability in early-onset autoimmune diabetes presentation in individuals with monogenic autoimmunity; the mechanism(s) underlying this is unclear. We examined whether type 1 diabetes (T1D) polygenic risk contributes to clinical phenotype in monogenic autoimmune diabetes. Individuals with monogenic autoimmune diabetes had higher T1D genetic risk scores compared with control cohorts, driven largely by increased presence of T1D-risk DR3-DQ2 haplotype.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the usefulness of DQ-genotyping in screening for celiac disease (CD) among type 1 diabetic (T1D) patients in a Saudi population, focusing on the frequency of DQ-genotypes, associated risks, and cost-effective screening strategies.
  • Involved 67 T1D patients with CD and 224 without, analyzing their HLA-DQ genotypes to compare risks of developing CD.
  • Results showed a significant correlation between homozygous DQ2.5/DR3-DQ2.5 genotypes and increased risk for CD, while only 4% of patients had no risk genotypes, confirming celiac serology tests
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the link between whole exome sequencing (WES) data and clinical features in children diagnosed with type 1 diabetes before age 5, analyzing 99 unrelated cases.
  • Of the participants, 8.1% had potentially harmful rare variants in MODY genes, which were associated with specific genetic risk factors and different clinical markers compared to those without these variants.
  • The findings suggest that WES may help identify distinct subtypes (endotypes) of type 1 diabetes and pave the way for tailored treatments in young patients.
View Article and Find Full Text PDF

Functional metagenomic analysis reveals potential inflammatory triggers associated with genetic risk for autoimmune disease.

J Autoimmun

September 2024

Crown Princess Victoria's Children's Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

To assess functional differences between the microbiomes of individuals with autoimmune risk-associated human leukocyte antigen (HLA) genetics and autoimmune protection-associated HLA, we performed a metagenomic analysis of stool samples from 72 infants in the All Babies in Southeast Sweden general-population cohort and assessed haplotype-peptide binding affinities. Infants with risk-associated HLA DR3-DQ2.5 and DR4-DQ8 had a higher abundance of known pathogen-associated molecular patterns and virulence related genes than infants with protection-associated HLA DR15-DQ6.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!